Blocking the renin–angiotensin–aldosterone system (RAAS) with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor blockers decreases high blood pressure and reduces morbidity and mortality in patients with chronic heart failure and chronic kidney disease [1,2]. The gene discussed is ACE; the disease is congestive heart failure.